China Biologic Collaborates with Blood Transfusion Institution to Strengthen R&D

| About: China Biologic (CBPO)

China Biologic Products, Inc. (NASDAQ:CBPO), a company based on blood plasma products, entered an R&D agreement with the Institute of Blood Transfusion of Chengdu, Sichuan Province. IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College. For China Biologic, the alliance will serve to strengthen its R&D capabilities and manufacturing processes.

Founded in 1958, IBT is the exclusive state-level institute of transfusion medicine. Its research areas include the safety of blood transfusions, blood immunology, transfusion disposable materials, blood biochemistry and molecular biology. Besides improving safe and efficient plasma collection, China Biologic hopes the collaboration will develop new plasma-derived products. China Biologic also gains access to IBT’s platform technologies, including recombinant protein therapeutics, monoclonal antibody technology and diagnostics.

China Biologic will provide partial funding, plasma, the use of its manufacturing facilities, and access to its research and development resources. IBT will supply specialized training and education to China Biologic’s research staff, and it will secure funding from national and provincial funding bodies.

China Biologic will have priority purchase rights to commercialize any new technologies or products that result from the collaboration.

Disclosure: none.